Literature DB >> 30456020

Revision Surgery for Vestibular Schwannomas.

Kevin A Peng1, Brian S Chen2, Mark B Lorenz3, Gregory P Lekovic1, Marc S Schwartz1, William H Slattery1, Eric P Wilkinson1.   

Abstract

Objectives  To describe clinical outcomes of patients undergoing revision surgery for vestibular schwannomas. Design  Retrospective case series. Setting  Tertiary private neurotologic practice. ParticipantsPatients who underwent revision surgeries for recurrent/residual vestibular schwannomas between 1985 and 2015. Main Outcome Measures  Degree of resection, facial nerve function, cerebrospinal fluid (CSF) leak. Results  A total of 234 patients underwent 250 revision surgeries for recurrent/residual vestibular schwannomas. Of these, 86 carried a diagnosis of neurofibromatosis type 2 (NF2). The mean number of prior surgeries was 1.26, and 197 (85%) prior surgeries had been performed elsewhere. The average age at surgery was 43. The most common approach employed at the time of revision surgery was translabyrinthine (87%), followed by transcochlear (6%), middle fossa (5%), and retrosigmoid (2%). Gross total resection was achieved in 212 revision surgeries (85%). Preoperative House-Brackmann facial nerve function was similar in non-NF2 and NF2 groups (mean: 2.7). Mean postoperative facial nerve function at last follow-up was 3.8 in the non-NF2 group and 3.9 in the NF2 group. History of radiation and the extent of resection were not associated with differences in facial nerve function preoperatively or postoperatively. CSF leaks occurred after 21 surgeries (8%), and six (2%) patients required reoperation. Conclusions  This is the largest series of revision surgery for vestibular schwannomas to date. Our preferred approach is the translabyrinthine craniotomy, which can be readily modified to include the transcochlear approach for improved access. CSF leak rate slightly exceeds that of primary surgery, and gross total resection is achievable in the vast majority of patients.

Entities:  

Keywords:  acoustic neuroma; microsurgery; middle fossa approach; retrosigmoid approach; translabyrinthine approach; vestibular schwannoma

Year:  2018        PMID: 30456020      PMCID: PMC6239869          DOI: 10.1055/s-0038-1635256

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  22 in total

1.  Removal of large or giant sporadic vestibular schwannomas via translabyrinthine approach: a report of 115 cases.

Authors:  Zhihua Zhang; Zhaoyan Wang; Qi Huang; Jun Yang; Hao Wu
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  2012-11-07       Impact factor: 1.538

2.  Extent of resection and the long-term durability of vestibular schwannoma surgery.

Authors:  Michael E Sughrue; Rajwant Kaur; Martin J Rutkowski; Ari J Kane; Gurvinder Kaur; Isaac Yang; Lawrence H Pitts; Andrew T Parsa
Journal:  J Neurosurg       Date:  2011-01-21       Impact factor: 5.115

Review 3.  Vestibular schwannoma management: What is the 'best' option?

Authors:  S A Rutherford; A T King
Journal:  Br J Neurosurg       Date:  2005-08       Impact factor: 1.596

4.  Management of 1000 vestibular schwannomas (acoustic neuromas): surgical management and results with an emphasis on complications and how to avoid them.

Authors:  M Samii; C Matthies
Journal:  Neurosurgery       Date:  1997-01       Impact factor: 4.654

5.  Are there modifiable risk factors to prevent a cerebrospinal fluid leak following vestibular schwannoma surgery?

Authors:  William R Copeland; Grant W Mallory; Brian A Neff; Colin L W Driscoll; Michael J Link
Journal:  J Neurosurg       Date:  2014-11-21       Impact factor: 5.115

6.  Vestibular schwannoma management. Part I. Failed microsurgery and the role of delayed stereotactic radiosurgery.

Authors:  B E Pollock; L D Lunsford; J C Flickinger; B L Clyde; D Kondziolka
Journal:  J Neurosurg       Date:  1998-12       Impact factor: 5.115

7.  Middle fossa versus retrosigmoid-transmeatal approach in vestibular schwannoma surgery: a prospective study.

Authors:  Vittorio Colletti; Francesco Fiorino
Journal:  Otol Neurotol       Date:  2003-11       Impact factor: 2.311

8.  Outcome after translabyrinthine surgery for vestibular schwannomas: report on 1244 patients.

Authors:  Jacob Bertram Springborg; Kåre Fugleholm; Lars Poulsgaard; Per Cayé-Thomasen; Jens Thomsen; Sven-Eric Stangerup
Journal:  J Neurol Surg B Skull Base       Date:  2012-06

9.  Surveillance after resection of vestibular schwannoma: measurement techniques and predictors of growth.

Authors:  Shan Tang; Andrew S Griffin; Julian A Waksal; C Douglas Phillips; Carl E Johnson; Joseph P Comunale; Sasan Karimi; Tiffany L Powell; Philip E Stieg; Philip H Gutin; Kevin D Brown; Matthew Sheehan; Samuel H Selesnick
Journal:  Otol Neurotol       Date:  2014-08       Impact factor: 2.311

10.  Revision surgery for residual or recurrent vestibular schwannoma.

Authors:  Simon Richard Mackenzie Freeman; Richard Thomas Ramsden; Shakeel Riaz Saeed; Firas Qaseem Alzoubi; Ricard Simo; Scott Alexander Rutherford; Andrew Thomas King
Journal:  Otol Neurotol       Date:  2007-12       Impact factor: 2.311

View more
  3 in total

1.  Comparison of Small Intestinal Submucosal Graft and Autologous Tissue in Prevention of CSF leak after Posterior Fossa Craniotomy.

Authors:  Douglas J Totten; Nauman F Manzoor; Kristen L Yancey; Robert J Yawn; David S Haynes; Alejandro Rivas
Journal:  J Neurol Surg B Skull Base       Date:  2021-03-12

2.  Treatment Analysis and Overall Survival Outcomes of Patients With Bilateral Vestibular Schwannoma.

Authors:  Khodayar Goshtasbi; Mehdi Abouzari; Tyler M Yasaka; Sina Soltanzadeh-Zarandi; Brooke Sarna; Harrison W Lin; Hamid R Djalilian
Journal:  Otol Neurotol       Date:  2021-04-01       Impact factor: 2.619

3.  Optimal Volume of the Residual Tumor to Predict Long-term Tumor Control Using Stereotactic Radiosurgery after Facial Nerve-preserving Surgery for Vestibular Schwannomas.

Authors:  Won Jae Lee; Jung Il Lee; Jung Won Choi; Doo Sik Kong; Do Hyun Nam; Yang Sun Cho; Hyung Jin Shin; Ho Jun Seol
Journal:  J Korean Med Sci       Date:  2021-04-26       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.